News

The US Food and Drug Administration has started making rejection letters that pharmaceutical companies traditionally keep ...
The U.S. Food and Drug Administration on Thursday published more than 200 of its so-called complete response letters to ...
The FDA has released an “initial batch“ of more than 200 complete response letters (CRLs) in efforts to boost transparency. | ...
The letters, many of which were already available online, detail why the regulators initially declined to approve some drugs.
The U.S. FDA publishes over 200 complete response letters to enhance transparency within the agency. Read more here.
The FDA published more than 200 letters that it sent to companies when it rejected their medicines, but the letters came with a caveat.
Investors have long asked the FDA to share its reasons for rejecting drugs, arguing that companies can use the agency’s silence on the matter to mislead the market.
A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving ...
Milestone Pharmaceuticals (MIST) stock falls amid a capital raise as FDA agrees to review its resubmitted NDA for heart therapy Cardamyst. Read more here.
The FDA on Thursday said it published more than 200 decision letters, known as complete response letters, that it issued in response to applications for approval of drugs or biological products ...